source
- With new data, Regenxbio to seek FDA approval of Duchenne gene therapyThough two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA leadership will have a “mandate on rare disease flexibility.”BioPharma Dive · 3mo ago↗ source
- STAT+: Three years of declining overdose deaths begets cautious optimism and some concernsThe next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning RoundsSTAT · 3mo ago↗ source
- STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage studyBiogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.STAT · 3mo ago↗ source